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Are Associated With
All-Cause Mortality and
Cardiovascular Outcomes
in the General PopulationIndividuals with systemic autoimmune disease
exhibit a heightened risk for cardiovascular disease
(CVD) (1). Antinuclear autoantibodies (ANA) have
been reported in approximately 25% of the general
population (2); yet, only a small fraction of those in-
dividuals will develop autoimmune disease. The sig-
niﬁcance of this “benign autoimmunity” is unknown,
and the role of ANA as a cardiovascular risk factor in
the general population has not been clearly deﬁned.
We examined the associations among ANA and
all-cause mortality and cardiovascular events in the
DHS (Dallas Heart Study), a multiethnic, population-
based, cohort study (2,3).
The study population included 2,803 participants
who were free of CVD, had no self-reported autoim-
mune disease with use of an immunosuppressive
medication, and had complete follow-up for events
through December 2010. Plasma ANA were measured
at baseline using an enzyme-linked immunosorbent
assay (Inova, San Diego, California) and reported
as enzyme-linked immunosorbent assay units (EU)
(2). HEp2-cell indirect immunoﬂuorescence (IF) is
used more commonly in clinical practice; however,
we have previously reported a high correlation ofANA EU with immunoﬂuorescence titers (r ¼ 0.8;
p ¼ 0.02) (2).
Mortality data were queried from the National
Death Index through 2010. Atherosclerotic cardio-
vascular disease (ASCVD) events were adjudicated,
and included cardiovascular death, myocardial in-
farction, coronary revascularization, and stroke (3).
Associations of log-transformed ANA with all-cause
mortality, cardiovascular death, and ASCVD were
assessed by Cox proportional hazards regression,
adjusting for: 1) age, race/ethnicity, and sex; and
2) model 1 plus hypertension, diabetes, smoking,
body mass index, estimated glomerular ﬁltration
rate, statin use, total cholesterol, triglycerides, and
high-density lipoprotein cholesterol. Sensitivity
analyses excluded participants with an ANA >65 EU
(n ¼ 150).
Participants with higher ANA were more likely to
be female and African-American (p < 0.0001 for
each). Higher ANA were seen in participants with
hypertension (p ¼ 0.02) and in nonsmokers
(p < 0.0001). We did not ﬁnd differences in ANA on
the basis of age, diabetes, hypercholesterolemia, and
metabolic syndrome.
Over a median 9.4-year follow-up, 158 total deaths,
54 cardiovascular deaths, and 157 ASCVD events
were recorded. After adjusting for age, sex, and
race/ethnicity, higher ANA were associated with all-
cause mortality (hazard ratio [HR] per 1 SD of log
[ANA]: 1.27; 95% conﬁdence interval [CI]: 1.10 to 1.46;
p ¼ 0.0008), cardiovascular death (HR: 1.42; 95% CI:
1.13 to 1.77; p ¼ 0.002), and ASCVD (HR: 1.17; 95% CI:
1.01 to 1.35; p ¼ 0.04) (Table 1). ANA remained inde-
pendently associated with all-cause mortality, car-
diovascular death, and ASCVD after adjustment for
CVD risk factors. The associations of ANA with
all-cause and cardiovascular death remained signiﬁ-
cant after excluding participants with ANA >65 EU
(immunoﬂuorescence titer of 1:160).
The major ﬁnding of this study is that higher ANA
are independently associated with all-cause mortal-
ity, cardiovascular death, and ASCVD in an ethnically
diverse, community-based population. Importantly,
these associations are evident at ANA levels below
those traditionally considered to be indicative of
autoimmune disease.
A limited number of studies have investigated as-
sociations of low-level autoimmunity with CVD (4,5).
Liang et al. (5) found that ANA positivity was associ-
ated with cardiovascular events and mortality after
adjusting for cardiovascular risk factors and autoim-
mune disease. However, ANA were measured for
clinical purposes, resulting in a prevalence of auto-
immune disease that was 10-fold higher than in the
TABLE 1 ANA Associations With Mortality Outcomes and Cardiovascular Events
Events (n)
Unadjusted
HR (95% CI)
Model 1
HR (95% CI)
Model 2
HR (95% CI)
All-cause mortality 158 1.29 (1.13–1.48) 1.27 (1.10–1.46) 1.26 (1.10–1.46)
p Value 0.0002 0.0008 0.002
Cardiovascular death 54 1.45 (1.17–1.79) 1.42 (1.13–1.77) 1.37 (1.10–1.73)
p Value 0.0006 0.002 0.01
ASCVD 157 1.16 (1.01–1.35) 1.17 (1.01–1.35) 1.18 (1.01–1.37)
p Value 0.04 0.04 0.04
Sensitivity Analysis in Participants With ANA <65 EU
All-cause mortality 145 1.31 (1.07–1.61) 1.28 (1.03–1.58) 1.25 (1.002–1.56)
p Value 0.01 0.02 0.047
Cardiovascular death 50 1.69 (1.19–2.40) 1.62 (1.13–2.30) 1.49 (1.02–2.17)
p Value 0.003 0.009 0.04
ASCVD 148 1.22 (0.99–1.50) 1.23 (1.0–1.51) 1.22 (0.98–1.51)
p Value 0.058 0.054 0.07
N ¼ 2,803. Hazard ratios (HRs) and 95% conﬁdence intervals (CIs) for 1 SD increase in log (ANA).
ANA ¼ antinuclear autoantibodies; ASCVD ¼ atherosclerotic cardiovascular disease; EU ¼ enzyme-linked immunosorbent assay unit(s).
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a population-based assessment of the implications of
low-level ANA.
The DHS is an observational cohort; thus, we
cannot determine whether the association between
ANA and adverse events is causal. These ﬁndings
raise the possibility that the presence of ANA signals
immunological events that are affecting vascular
health, although the exact role requires further study.
Several study limitations are noteworthy. Baseline
ANAwere performed; thus, we cannot account for vari-
ability in ANA or autoimmunity over time. Exclusion
of participants with autoimmune disease was on the
basis of self-report, rather than physician evaluation.
In conclusion, increasing ANA are independently
associated with all-cause mortality, cardiovascular
death, and ASCVD in a representative multiethnic
population-based cohort. ANA may identify in-
dividuals at increased risk of death and ASCVD
independent of traditional risk factors or clinical
autoimmune disease, a ﬁnding that potentially
affects a substantial percent of the population.*Elizabeth Blair Solow, MD
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Joggers Do Not Have
Lower Mortality Rates
Than Strenuous JoggersThe recently published paper by Schnohr et al. (1) on
jogging and long-term mortality concluded that there
was a U-shaped association between all-cause mor-
tality and dose of jogging, and that low-intensity
